Vaccinating newborns against Hepatitis B

series event

This World Immunisation Week, join us for a series of webinars hosted by LSHTM Vaccine Centre between Friday 24 April to Friday 1 May 2020.

World Immunisation Week 2020 event image

Hepatitis B is an infection of the liver caused by a virus that is spread through blood and body fluids. Worldwide, over half a million people die from this infection each year, whilst we have a vaccine to prevent it. Hepatitis B vaccination is routinely available as part of the NHS vaccination schedule and is offered to all babies at 8, 12 and 16 weeks of age. It is also part of the routine vaccines given at birth in many endemic countries around the globe, as recommended by the WHO- nevertheless it does not reach all who should receive it.

In July 2019, the World Health Organization (WHO) announced that 189 countries now provide the vaccine for infants on a national level, but the global coverage of the birth dose is just 42%. The birth dose is significant for a number of reasons. Ninety percent of babies and up to 50% of young children will progress to chronic hepatitis B if they are infected. The vaccine gives protection against the hepatitis B virus, which is a major cause of serious liver disease, including scarring of the liver (cirrhosis) and liver cancer.

This session will address the global burden of Hep B and focus on the value of the birth dose. It will discuss reasons why it is not implemented more successfully and propose what could be done about this issue.

Speakers

Professor Beate Kampmann: Professor of Paediatric Infection and Immunity, Director of the Vaccine Centre, LSHTM & MRC Unit The Gambia at LSHTM Theme Leader

Professor Beate Kampmann joined the LSHTM from Imperial College London in May 2018 and is the Director of The Vaccine Centre @ LSHTM. She trained as a clinician-scientist in Paediatric Infectious Diseases in Germany, UK, France, USA and South Africa. Beate holds a Chair in Paediatric Infection & Immunity and was appointed as the Scientific Director (Theme Leader) for Vaccinology research at the MRC Unit The Gambia in July 2010. She directs a comprehensive childhood infection research program both in the UK and sub-saharan Africa.

As one of the three theme leaders at the MRC Unit the Gambia at LSHTM, she oversees all research activities in infant immunology, childhood tuberculosis and molecular diagnostics, which range from basic research into innate and acquired immune responses to infection and vaccination in pregnant women and infants and the conduct of clinical trials of novel vaccines, adjuvants adn administration modalities.

Over the last few years she has conducted a number of studies in both UK and West Africa investigating the scientific and implementation challenges of maternal immunization.

She is the director of IMPRINT- the IMmunising PRegnant women and INfants network, one of the 5 MRC-funded networks for vaccines (www.imprint-network.co.uk).

Dr Maud Lemoine: Reader and Honorary Consultant in Hepatology at St Mary’s Hospital, Imperial College London, UK

Dr Maud Lemoine is a Reader and Honorary Consultant in Hepatology at St Mary’s hospital, Imperial College London, UK. She completed her medical degree and PhD in Paris, France. She also graduated in political sciences from the Institute of Political Studies in Paris. Her research activities are mainly focused on the prevention and management of viral hepatitis in resource-limited countries, mainly in Africa. Since 2011, she has been working with the Medical Research Council (MRC) The Gambia unit, as part of the hepatitis B PROLIFICA (Prevention of Liver Fibrosis and Cancer in Africa) programme in The Gambia and Senegal.

She has been member of the WHO guideline development group for the management of chronic hepatitis B/C and is regularly commissioned by the WHO viral hepatitis unit for external reviews and consultancies.

Dr Gibril Ndow, MRC Unit The Gambia at LSHTM and Imperial College London

Dr Ndow is clinical research fellow at the Division of Digestive Diseases, Imperial College London. He is based at the MRC Unit The Gambia at LSHTM where he leads the Viral Hepatitis Research group, supervised by Dr Maud Lemoine and Prof Umberto D’Alessandro.

Join the webinar

Feel free to submit your questions about this webinar session by entering your enquiries via this form.

Full programme on LSHTM's World Immunisation Week 2020

Admission

Follow webinar link. Free and open to all.

Contact

Vaccine Centre

Where and when

Date

Monday 27 April 2020

Time

16:00 - 17:00

Date and time zone is UK

Speaker(s)

Professor Beate Kampmann (LSHTM), Dr Maud Lemoine (Imperial College London) & Dr Gibril Ndow (MRC Unit The Gambia at LSHTM & Imperial College London)

Admission

Follow webinar link. Free and open to all.

Contact

Vaccine Centre

Add to Calendar 2020-04-27 16:00:00 2020-04-27 17:00:00 Vaccinating newborns against Hepatitis B Hepatitis B is an infection of the liver caused by a virus that is spread through blood and body fluids. Worldwide, over half a million people die from this infection each year, whilst we have a vaccine to prevent it. Hepatitis B vaccination is routinely available as part of the NHS vaccination schedule and is offered to all babies at 8, 12 and 16 weeks of age. It is also part of the routine vaccines given at birth in many endemic countries around the globe, as recommended by the WHO- nevertheless it does not reach all who should receive it. In July 2019, the World Health Organization (WHO) announced that 189 countries now provide the vaccine for infants on a national level, but the global coverage of the birth dose is just 42%. The birth dose is significant for a number of reasons. Ninety percent of babies and up to 50% of young children will progress to chronic hepatitis B if they are infected. The vaccine gives protection against the hepatitis B virus, which is a major cause of serious liver disease, including scarring of the liver (cirrhosis) and liver cancer. This session will address the global burden of Hep B and focus on the value of the birth dose. It will discuss reasons why it is not implemented more successfully and propose what could be done about this issue. Speakers Professor Beate Kampmann: Professor of Paediatric Infection and Immunity, Director of the Vaccine Centre, LSHTM & MRC Unit The Gambia at LSHTM Theme Leader Professor Beate Kampmann joined the LSHTM from Imperial College London in May 2018 and is the Director of The Vaccine Centre @ LSHTM. She trained as a clinician-scientist in Paediatric Infectious Diseases in Germany, UK, France, USA and South Africa. Beate holds a Chair in Paediatric Infection & Immunity and was appointed as the Scientific Director (Theme Leader) for Vaccinology research at the MRC Unit The Gambia in July 2010. She directs a comprehensive childhood infection research program both in the UK and sub-saharan Africa. As one of the three theme leaders at the MRC Unit the Gambia at LSHTM, she oversees all research activities in infant immunology, childhood tuberculosis and molecular diagnostics, which range from basic research into innate and acquired immune responses to infection and vaccination in pregnant women and infants and the conduct of clinical trials of novel vaccines, adjuvants adn administration modalities. Over the last few years she has conducted a number of studies in both UK and West Africa investigating the scientific and implementation challenges of maternal immunization. She is the director of IMPRINT- the IMmunising PRegnant women and INfants network, one of the 5 MRC-funded networks for vaccines (www.imprint-network.co.uk). Dr Maud Lemoine: Reader and Honorary Consultant in Hepatology at St Mary’s Hospital, Imperial College London, UK Dr Maud Lemoine is a Reader and Honorary Consultant in Hepatology at St Mary’s hospital, Imperial College London, UK. She completed her medical degree and PhD in Paris, France. She also graduated in political sciences from the Institute of Political Studies in Paris. Her research activities are mainly focused on the prevention and management of viral hepatitis in resource-limited countries, mainly in Africa. Since 2011, she has been working with the Medical Research Council (MRC) The Gambia unit, as part of the hepatitis B PROLIFICA (Prevention of Liver Fibrosis and Cancer in Africa) programme in The Gambia and Senegal. She has been member of the WHO guideline development group for the management of chronic hepatitis B/C and is regularly commissioned by the WHO viral hepatitis unit for external reviews and consultancies. Dr Gibril Ndow, MRC Unit The Gambia at LSHTM and Imperial College London Dr Ndow is clinical research fellow at the Division of Digestive Diseases, Imperial College London. He is based at the MRC Unit The Gambia at LSHTM where he leads the Viral Hepatitis Research group, supervised by Dr Maud Lemoine and Prof Umberto D’Alessandro. Join the webinar Feel free to submit your questions about this webinar session by entering your enquiries via this form. Full programme on LSHTM's World Immunisation Week 2020 Vaccine Centre Europe/London public

Events notices

For more information on how we use your data, please see our events privacy notice and our data protection pages.

LSHTM uses third-party platforms, which are not affiliated with LSHTM directly, to host our virtual events. Please see the Zoom privacy notice and Collaborate privacy notice for these.

For any accessibility requirements, please get in touch with the event contact listed above.

Sign up for our newsletter

Subscribe to our monthly newsletter and get all the latest research news, views, videos and event listings from the School.

Subscribe to RSS feed

London School of Hygiene & Tropical Medicine